[
  {
    "ts": "2025-03-11T17:37:28+00:00",
    "headline": "Agilent Technologies (NYSE:A) Expands Cancer Diagnostic Kit Indications In EU For NSCLC And Melanoma",
    "summary": "Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma. While this significant advancement in oncology diagnostics highlights the company's innovative edge, Agilent's stock saw a weekly decline of 3.51%. This price movement occurred against a backdrop of broader market volatility, driven by economic and political uncertainties including the Trump...",
    "url": "https://finance.yahoo.com/news/agilent-technologies-nyse-expands-cancer-173728402.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3824f3a1-59fb-3a2e-8b01-ad0a011c7e92",
      "content": {
        "id": "3824f3a1-59fb-3a2e-8b01-ad0a011c7e92",
        "contentType": "STORY",
        "title": "Agilent Technologies (NYSE:A) Expands Cancer Diagnostic Kit Indications In EU For NSCLC And Melanoma",
        "description": "",
        "summary": "Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma. While this significant advancement in oncology diagnostics highlights the company's innovative edge, Agilent's stock saw a weekly decline of 3.51%. This price movement occurred against a backdrop of broader market volatility, driven by economic and political uncertainties including the Trump...",
        "pubDate": "2025-03-11T17:37:28Z",
        "displayTime": "2025-03-11T17:37:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dF3MhqhVQlxOrPlZ6576PQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iKEosOYcHiWIA3wbQNTRmQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/agilent-technologies-nyse-expands-cancer-173728402.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/agilent-technologies-nyse-expands-cancer-173728402.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "A"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]